Skip to main content
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Published Web Location
http://europepmc.org/articles/PMC4484416?pdf=renderNo data is associated with this publication.
Abstract
Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By identifying novel predictive bioma
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.